Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's (BHVN) new small molecule class of degraders from the monoclonal ...
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results